FDA accepts BioMarin’s VOXZOGO sNDA, sets Feb. 28, 2027 PDUFA date

The filing seeks full approval in children with achondroplasia, backed by long-term data from three ongoing studies including adult height, body proportionality and arm span outcomes.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.